Jose Garcia-gimenez PhD

Dr. Jose Luis Garcia-Gimenez, PhD, is the CEO of Epidisease SL, Valencia, Spain. He is the principal investigator at the Consortium Center for Biomedical Network Research (CIBER-ISCIII) in the area of rare diseases and the Principal Investigator at the Group of Epigenetics and Translational Epigenomics in the Biomedical Research Institute INCLIVA. Dr. García-Giménez is an associate professor in the Department of Physiology in the Medicine and Dentistry School (University of Valencia). Professor in the Master's program of Physiology, Master's in Biomedicine, and Master's in Rare Diseases at the University of Valencia.

Bachelor in Chemical Science in 2002 and a Bachelor in Biochemistry in 2004 (University of Valencia). PhD. Degree in Chemistry in 2007 (University of Valencia), he was invited Post-Doc fellow in Hake’s lab at the Adolf Butenandt Institute, LMU University, Munich (Germany). He received mentoring in entrepreneurship during the MIT LinQ program (two editions 2016 and 2017) and CaixaImpulse Program (2018) My research is focused on the analysis of epigenetic mechanisms involved in human diseases, particularly in rare diseases.

More than 15 years of continuous research as a PI and collaborator in national and international projects. In 2018, he received CaixaImpulse Award to lead the valorization plan of the HistShock test. Dr. García-Giménez is the inventor of 4 technologies related to epigenetic biomarkers, protected by 4 different patent families.